Prognostic impact of the coexpression of CD34 and CXCR-4 and other prognostic variables as regards overall survival and relapse-free survival
. | Overall survival; n = 90 . | . | Relapse-free survival; n = 62 . | . | ||
|---|---|---|---|---|---|---|
| Variable . | Relative risk (95% CI) . | P . | Relative risk (95% CI) . | P . | ||
| Coexpression of CD34 and CXCR-4 in more than 1% of cells | 3.19 (1.62-6.27) | .001 | 3.92 (1.57-9.8) | < .001 | ||
| Presence of FIt3/ITDs | 3.01 (1.59-5.66) | .001 | 2.86 (1.2-6.7) | .015 | ||
| Unfavorable cytogenetic abnormalities* | 2.26 (0.93-5.47) | .014 | 3.0 (1.0-9.3) | .047 | ||
| Age | 1.02 (1.00-1.03) | .024 | 0.99 (0.98-1.02) | .490 | ||
. | Overall survival; n = 90 . | . | Relapse-free survival; n = 62 . | . | ||
|---|---|---|---|---|---|---|
| Variable . | Relative risk (95% CI) . | P . | Relative risk (95% CI) . | P . | ||
| Coexpression of CD34 and CXCR-4 in more than 1% of cells | 3.19 (1.62-6.27) | .001 | 3.92 (1.57-9.8) | < .001 | ||
| Presence of FIt3/ITDs | 3.01 (1.59-5.66) | .001 | 2.86 (1.2-6.7) | .015 | ||
| Unfavorable cytogenetic abnormalities* | 2.26 (0.93-5.47) | .014 | 3.0 (1.0-9.3) | .047 | ||
| Age | 1.02 (1.00-1.03) | .024 | 0.99 (0.98-1.02) | .490 | ||
To more accurately define the significance of the observed correlation between prognosis and the percentages of cells coexpressing CXCR-4 and CD34, we performed a multivariate Cox regression analysis with CXCR-4/CD34 coexpression, the presence FIt3 mutations, cytogenetics, and age as variables in the regression analysis. Results are presented as relative risks with the 95% confidence intervals and respective P values.
n = the number of samples included in the analysis.
See legend to Table 1.